• Change from baseline in pre-bronchodilator percent predicted forced expiratory volume in 1 second (FEV1) at week 24
• Change from baseline in the 6-minute walk distance at week 24
• Change from baseline in the 36-item short form health survey (SF-36) physical component summary score at week 24
• Change from baseline in the Transition Dyspnea Index (TDI) score at week 24
• Incidence of moderate to severe COPD exacerbations through week 24

The purpose of this study is to evaluate the safety and effectiveness of infliximab (Remicade) in patients with Chronic Obstructive Pulmonary Disease (COPD). Infliximab (Remicade) targets specific proteins in the body's immune system to help control the development of inflammation to help reduce painful disease.

Chronic Obstructive Pulmonary Disease (COPD) is a smoking-related inflammatory lung disease that results in reduced lung function, causing the symptoms or problems that you have when breathing. COPD includes both chronic bronchitis and emphysema. The symptoms of COPD are cough, sputum (phlegm) production, breathlessness, and wheezing. Advanced disease may also involve changes in appetite and weight loss. The drug used in this study is called Remicadeâ, and the active component is called infliximab. Infliximab binds to and blocks the activity of a naturally occurring substance in the body called tumor necrosis factor alpha or TNFa, which may be associated with inflammation and a decrease in lung function.The purpose of this study is to evaluate the safety and effectiveness of infliximab in the treatment of patients with symptoms of moderate to severe COPD.Patients will be receive infusions of either placebo, 3 mg/kg infliximab or 5mg/kg infliximab at weeks 0, 2, 6, 12, 18, and 24.Safety evaluations will be performed at specified intervals throughout the study and will consist of laboratory tests, vital signs (such as blood pressure), physical examinations and the occurrence and severity of adverse events as well as other study specific procedures.

Patients will receive infusions of either placebo, 3 mg/kg infliximab or 5mg/kg infliximab at weeks 0, 2, 6, 12, 18, and 24.

• COPD
• Chronic Obstructive Pulmonary Disease

Inclusion Criteria:

• Patients must have moderate or severe COPD
• Patients must have at least one episode of COPD-related symptoms (eg, cough, sputum production, shortness of breath) within 2 months prior to screening     

Exclusion Criteria:

• Patients must not have asthma as main component of obstructive airway disease
• Patients must not have had a moderate or severe exacerbation of COPD within previous 1 month